Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Cash: 2009-2025

Historic Change in Cash for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $3.9 million.

  • Gyre Therapeutics' Change in Cash rose 1793.07% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 340.24%. This contributed to the annual value of -$21.7 million for FY2024, which is 360.33% down from last year.
  • Gyre Therapeutics' Change in Cash amounted to $3.9 million in Q3 2025, which was down 81.76% from $21.4 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Change in Cash peaked at $52.7 million during Q1 2021, and registered a low of -$52.3 million during Q3 2022.
  • Over the past 3 years, Gyre Therapeutics' median Change in Cash value was $2.4 million (recorded in 2023), while the average stood at $1.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 372.39% in 2021, then skyrocketed by 1,793.07% in 2025.
  • Gyre Therapeutics' Change in Cash (Quarterly) stood at -$14.8 million in 2021, then spiked by 209.58% to $16.2 million in 2022, then tumbled by 54.22% to $7.4 million in 2023, then tumbled by 154.55% to -$4.1 million in 2024, then surged by 1,793.07% to $3.9 million in 2025.
  • Its Change in Cash stands at $3.9 million for Q3 2025, versus $21.4 million for Q2 2025 and $3.2 million for Q1 2025.